Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0NRRBO
ADC Name	ARB102-IR700
Synonyms	ARB102 IR700 Click to Show/Hide
Drug Status	Investigative
Indication	In total 3 Indication(s) Colorectal cancer [ICD11:2B91] Investigative Gastric cancer [ICD11:2B72] Investigative Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Anti-CDH17 mAb ARB102		Antibody Info
Antigen Name	Cadherin-17 (CDH17)		Antigen Info
Payload Name	IRDye 700DX		Payload Info
Linker Name	Undisclosed
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Sarotalocan

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 4 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 36.97	%	SNU-C1 cells	Colon adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 37.92	%	LoVo cells	Colon adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 53.65	%	AsPC-1 cells	Pancreatic ductal adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 58.37	%	AsPC-1 cells	Pancreatic ductal adenocarcinoma

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	0.12	ug/mL	LoVo cells	Colon adenocarcinoma
Half Maximal Effective Concentration (EC50)	49	ug/mL	SW480 cells	Colon adenocarcinoma
Half Maximal Effective Concentration (EC50)	74	ug/mL	SNU-C1 cells	Colon adenocarcinoma
Half Maximal Effective Concentration (EC50)	86	ug/mL	AsPC-1 cells	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 36.97% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	SNU-C1 CDX model
In Vitro Model	Colon adenocarcinoma	SNU-C1 cells		CVCL_1708
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.92% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	LoVo CDX model
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.65% (Day 28)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	AsPC-1 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.37% (Day 21)	High CDH17 expression (CDH17 +++)
Method Description	The tumor-bearing mice were subjected to three cycles of PIT treatment, once per week.
In Vivo Model	AsPC-1 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.12 ug/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	49.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	74.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Colon adenocarcinoma	SNU-C1 cells		CVCL_1708
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	86.00 ng/mL	High CDH17 expression (CDH17 +++)
Method Description	GI cancer cells were treated with PIT and cell viability was measured by MTT assay to determine EC50. Data is presented as mean SEM (n=3).
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

References

Ref 1	Cadherin-17 Targeted Near-Infrared Photoimmunotherapy for Treatment of Gastrointestinal Cancer. Mol Pharm. 2020 Oct 5;17(10):3941-3951. doi: 10.1021/acs.molpharmaceut.0c00700. Epub 2020 Sep 24.